HUE028331T2 - N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás - Google Patents

N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás Download PDF

Info

Publication number
HUE028331T2
HUE028331T2 HUE03798156A HUE03798156A HUE028331T2 HU E028331 T2 HUE028331 T2 HU E028331T2 HU E03798156 A HUE03798156 A HU E03798156A HU E03798156 A HUE03798156 A HU E03798156A HU E028331 T2 HUE028331 T2 HU E028331T2
Authority
HU
Hungary
Prior art keywords
antibody
ser
human
leu
peptide
Prior art date
Application number
HUE03798156A
Other languages
English (en)
Inventor
Marc Hubert Mercken
Marc Maria Pierre Pelagie Vandermeeren
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE028331T2 publication Critical patent/HUE028331T2/hu

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Claims (7)

  1. hidÎ-CSONKOO' ß-AMILÖÖ> ELLENI MÖN0KLCE4ÁLÍI ELLEN ANYAGI, KÉSEÍTMENY, ELJÁRÁS ÈS ALKALMAZÁS Szabadalmi 8gé»y|m»tí>k t, Mooekletiâlis: dlenaayag, amelÿ specitikussn Mispmn aa ABlLMtérje <3teH-nàl BACH-l-gyel fortém hasítása «tán kapott Aßll-x pepiidet egyéb Akfoiragpiensékre adott kermzírsatóo. aéïfâl, ahol a ímmokkieáMS ellenanyag specifikusán folisæen «à {EsàdsïeiàzjLÎ hasítási hely «IsS 5-7 batöáte amiaosavät, mm a Seq Mbfo,:l és Saq là. No.;2 szerinti szekvenciát, vagy az ß-sBekreta;;Π hasítási hs% első 5-? sgéréradátii mmaôsavâh mm a Seq M bio.:3 és Seq U Hfofo szedné szekvenciát. Ί M L Igénypetst saersaÁ mpaokíoösiis ellenanyag, azzal jelkstezw, hogy áz Api 1A pepiid emberi Api 1-40.
  2. 3. Ás L vagy 2. igénypont szerinti ellenanyag, amely kim«talítstő modo« címkézett. 4, A 3. igénypont szenmi ellenanyag, ahol a ksnutatható eímfce mdioaktív jelölés, enzi®}efolé§, laaakesssceas jelölés vagy ttuoreszeens jelölés,
  3. 5, Az Id/igëaypostok bâiftïdyike szerinti eUeaaayag»-aaa^ly .feordözétt immoinikáli.
  4. 6. As I -S. igétrypontok hàmfoiyike szerinti ellenanyag, assoiym à Belgiaa Coordinated Collections of Mfcrootganteaas-nál 2003. angosztus \9'φ&amp; rendié LMBP 5;#6CB ás LMBP 5897CB letéti szám«» letétbe helyeselt jMPRD/feAßl 3/1 ás MJPRDdxÄßil/2 htbndomaseitek Mpresszalsmk. %. A 20()2. augusztus IR-en a Belgian Coordinated Collections of Microorgamsms-ml rendre LMBP 5896CB és LMBP 5897CB: letéti számon létéibe helyezett I&amp;JFRD/feApil/l és JMPRD/hAßU/2 hilmdómasejtek
  5. 8, Isununvizsgáiati módszer mtniabsö AFMshárje Clitl Bőéi BACEd-gyel történt hasítása után kapott Aßii-x pepiM meghatárosására vagy kimutatására, amely eljárás magában foglalja a minta érintkezietését 1-3. Igénypontok bármelyike szerinti, AßlLx pepiid elleni ellenanyaggal és annak meghatározását, bogf képződött' e komplex az ellenanyag; és az Aßl l-x peptid közöm % B||áíás szövetmintában AFF-febérjs Olull-aéi BACiE-l-gyél tânèni háshásá «ián kapott Aßl l-x pepttl! jelenlétének kimutatására, amely eljárás- magában foglalja a kővetkezőket: alahy iésfoffoi származó szőveímlma. édntkeztetése képalkotó eljárásban hatásos mennyiségű, 3. vagy 4. igénypont szériöít, kitntdathfoban uiíttkézeít ellenanyaggal, ás «..címke kknutaiása, ezáltal a szőveímmtáfean az Api 1 -x pepiid jeksiétáuek mégáüapitása. 19. A % igénypontszerinti eljárás, ahol a tómwiaih»tó «iodes címkézett ellenanyagi« a 6. igénypont szénné, legalább egyik bsbridómare.·t espresszálja
  6. 11. BÍíms tesífoiyssdékOiiíííábsn APF-Míé# Gla'l 1-náJ BACE-l-gye! tósléni hasítása mán kapott Aß| 1-X pepiid jelenlétének kímaiatására, aœ# «yáras magában fdgiaí|a a követelőket: alanjr testiből .gteató i«stíöl>nddkfp5«ía: árimkeztetáss képalkotó eljárásban hatásos mentsyiségá*· 3. vagy 41 igénypom szerinti, kte^^ltósít.stofc^ett4ite»aaya^:al, és scímke kíístitaldsa. ezáltal a testKslyaPokmístában az Mbi-x peptid jólonláténektnegáíainiása. i%. A 11, igénypont szerinti etjárás, almi a Mmoíatbalóa« CiöAégetíi eilemmyágot a ?. igénypont szerinti legalább egy tk éibrklémasejl: exprexszália,
  7. 13, M Eb, ígésypoPtok básöí&amp;lyíke szeréi« «liena-iyag alkalmazása ß-anbioidbsi kapcsolatos betegség ín vkro diagnoszíszállsáza, 14; Diagnosztikai készítmény, aso# Wtátoaz 1-6. fénypontok bármelyike szcrM ellenanyagot és gyógjAszatilag el'fógadbató hordozót. iS, Ipipmhyjzsgslatra szolgáló készlet jhamiloiddai kapcsolatos betegség: diagrmsztizáiására, amely tanalmaz 2-S. igéoyponiöípbármslyike szénát! eSmaayagot és hordozol sz eilenääiysg szársíéra.
HUE03798156A 2002-09-27 2003-09-09 N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás HUE028331T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/011062 WO2004029629A1 (en) 2002-09-27 2002-09-27 N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
HUE028331T2 true HUE028331T2 (hu) 2016-12-28

Family

ID=32039081

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE03798156A HUE028331T2 (hu) 2002-09-27 2003-09-09 N-11-csonkolt ß-amiloid elleni monoklonális ellenanyag, készítmény, eljárás és alkalmazás

Country Status (14)

Country Link
US (2) US9329189B2 (hu)
EP (1) EP1546734B1 (hu)
JP (3) JP2006513988A (hu)
CN (2) CN101367875B (hu)
AU (1) AU2003266378B2 (hu)
CA (1) CA2498058C (hu)
CY (1) CY1117387T1 (hu)
DK (1) DK1546734T3 (hu)
ES (1) ES2560853T3 (hu)
HK (1) HK1081647A1 (hu)
HU (1) HUE028331T2 (hu)
PT (1) PT1546734E (hu)
SI (1) SI1546734T1 (hu)
WO (2) WO2004029629A1 (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EA200501524A1 (ru) * 2003-03-28 2006-06-30 Сентокор, Инк. Антитела против амилоида, композиции, способы и применения
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
NZ552480A (en) 2004-07-30 2010-01-29 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods of using same
WO2006039470A2 (en) * 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
ES2259270B1 (es) * 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AU2006320392B2 (en) 2005-11-30 2013-01-17 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
ES2527661T3 (es) 2005-11-30 2015-01-28 Abbvie Inc. Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
BRPI0619748B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
PT1996621E (pt) * 2006-03-30 2010-03-08 Glaxo Group Ltd Anticorpos contra o péptido beta-amilóide
EP2043687A4 (en) * 2006-06-29 2010-03-17 Centocor Ortho Biotech Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2008156622A1 (en) * 2007-06-12 2008-12-24 Ac Immune S.A. Humanized antibodies to amyloid beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RS53174B (en) * 2007-10-05 2014-06-30 Genentech Inc. USE OF ANTIAMYLOID BETA ANTIBODY IN THE EVENT OF ANY DISEASE
RU2571859C2 (ru) * 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
CA2703050A1 (en) * 2007-10-15 2009-04-23 Janssen Pharmaceutica Nv Anti-amyloid antibodies, compositions, methods and uses
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
CN101463085B (zh) * 2009-01-16 2011-09-14 清华大学 与A-beta寡聚体特异性结合的基因工程单克隆抗体
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
SG183229A1 (en) 2010-03-10 2012-09-27 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012123562A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Diagnostic antibody assay
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
JP6499079B2 (ja) 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
EP3221362B1 (en) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
EP3221361B1 (en) 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
KR20170085595A (ko) 2014-12-10 2017-07-24 제넨테크, 인크. 혈뇌 장벽 수용체 항체 및 사용 방법
AU2016354688B2 (en) 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN111770935A (zh) 2018-02-27 2020-10-13 株式会社岛津制作所 特异性识别APP669-x的N末端的抗体及免疫测定法
AU2019354965A1 (en) 2018-10-04 2021-05-06 University Of Rochester Improvement of glymphatic delivery by manipulating plasma osmolarity
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
JP7207517B2 (ja) 2019-03-01 2023-01-18 株式会社島津製作所 Ａｐｐ６６９－７１１の測定方法、及び測定用キット
JP7299566B2 (ja) 2019-07-05 2023-06-28 株式会社島津製作所 アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法
EP4185612A1 (en) 2020-07-23 2023-05-31 Othair Prothena Limited Anti-abeta antibodies
CN112540180B (zh) * 2020-11-06 2022-03-29 华中科技大学 用于检测人淀粉样蛋白-β双抗夹心ELISA检测试剂盒
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743827B2 (en) * 1997-04-09 2002-02-07 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
DE60106394T3 (de) 2000-02-24 2013-07-25 Washington University St. Louis Humanisierte antikörper, die amyloid beta peptid sequestrieren
WO2002047466A2 (en) 2000-10-27 2002-06-20 The Johns Hopkins University School Of Medicine Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
CN103687876A (zh) * 2011-07-15 2014-03-26 詹森药业有限公司 特异性针对β-淀粉样蛋白x-37的单克隆抗体及其用途

Also Published As

Publication number Publication date
EP1546734B1 (en) 2015-11-11
CA2498058A1 (en) 2004-04-08
US20170192016A1 (en) 2017-07-06
WO2004029629A1 (en) 2004-04-08
CN100418984C (zh) 2008-09-17
US9329189B2 (en) 2016-05-03
ES2560853T3 (es) 2016-02-23
WO2004029630A1 (en) 2004-04-08
JP2017149719A (ja) 2017-08-31
CN101367875A (zh) 2009-02-18
AU2003266378B2 (en) 2010-01-21
JP2014208678A (ja) 2014-11-06
US9939452B2 (en) 2018-04-10
DK1546734T3 (en) 2016-02-08
CN101367875B (zh) 2013-06-12
CY1117387T1 (el) 2017-04-26
PT1546734E (pt) 2016-03-01
CA2498058C (en) 2013-02-12
CN1685236A (zh) 2005-10-19
JP6420072B2 (ja) 2018-11-07
HK1081647A1 (en) 2006-05-19
AU2003266378A1 (en) 2004-04-19
JP2006513988A (ja) 2006-04-27
EP1546734A1 (en) 2005-06-29
US20060127954A1 (en) 2006-06-15
SI1546734T1 (sl) 2016-02-29

Similar Documents

Publication Publication Date Title
US9939452B2 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
EP0683234B2 (en) Antibody against beta-amyloid or their derivative and use thereof
JP3115606B2 (ja) βＡ４ペプチドに特異的なモノクローナル抗体
US5955317A (en) Antibodies to β-amyloids or their derivatives and use thereof
JP3553592B2 (ja) 可溶性β−アミロイド・ペプチドの検出のための方法及び組成物
US7807157B2 (en) Monoclonal antibodies and use thereof
EP2189526B1 (en) Antibody binding specifically to tdp-43 aggregate
US5985581A (en) Use of presenilin-1 for diagnosis of alzheimers disease
NZ541453A (en) Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof
JP4374316B2 (ja) β−アミロイドまたはその誘導体に対する抗体およびその用途
US5849600A (en) Diagnostic assays for Alzheimer&#39;s disease
EP2224000A1 (en) Antibody and use thereof
WO2007022015A1 (en) Methods to evaluate amyloid beta-lowering agents using wild-type mice
JP2955082B2 (ja) ヒトカルシトニンのｎ末端部分を特異的に認識するモノクローナル抗体
JP4037933B2 (ja) 抗ヒトカルシトニンモノクローナル抗体
JP2014520825A (ja) モノクローナル抗体に対して特異的なβ−アミロイドｘ−３７およびその使用